This Special Communication summarizes published evidence about the causes of elevated prescription drug prices in the United States and proposes policy options to mitigate the effects of high prices while preserving incentives for development and innovation.
This Viewpoint describes 6 pilot programs from the Centers for Medicare & Medicaid Services aimed at lowering Part B drug costs by discussing their application to cancer treatments.
This commentary discusses a survey study published in JAMA Dermatology that described the changes in the prices of commonly prescribed dermatologic drugs at national chain pharmacies over a 6-year period.
This Viewpoint describes differences between various cancer value frameworks and provides recommendations for improving them for clinicians, patients, and payers.
This Viewpoint summarizes the performance to date of the Affordable Care Act and discusses additional laws and regulations that might be needed to ensure continued reform.
This study analyzed expenditures for outpatient pharmacy products used by publicly insured children with serious chronic illness during 3 years.